Wockhardt shines on securing USFDA`s approval for ZAYNICH
Wockhardt is currently trading at Rs. 2166.05, up by 135.35 points or 6.67% from its previous closing of Rs. 2030.70 on the BSE.
The scrip opened at Rs. 2377.95 and has touched a high and low of Rs. 2420.00 and Rs. 2128.30 respectively. So far 445652 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2,420.00 on 1-Jun-2026 and a 52 week low of Rs. 1086.80 on 23-Mar-2026.
Last one week high and low of the scrip stood at Rs. 2,420.00 and Rs. 1,382.95 respectively. The current market cap of the company is Rs. 34935.82 crore.
The promoters holding in the company stood at 49.08%, while Institutions and Non-Institutions held 18.08% and 32.84% respectively.
Wockhardt has secured U.S. Food and Drug Administration’s (USFDA) approval for ZAYNICH (cefepime and zidebactam), a novel intravenous antibiotic for the treatment of adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative pathogens. ZAYNICH previously received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the USFDA. ZAYNICH is the first New Chemical Entity fully developed and commercialized by an Indian pharmaceutical company to receive an USFDA approval.
The USFDA approval was based, in part, on the results from ENHANCE-1, a Phase 3, randomized, double-blind, multicenter study which evaluated the efficacy, safety and tolerability of ZAYNICH compared with meropenem in the treatment of hospitalized adults with cUTI or acute pyelonephritis (AP). ZAYNICH demonstrated efficacy at the primary endpoint, achieving a composite clinical cure and microbiological response rate of 89.0% versus 68.4% for meropenem Treatment difference 20.6% (95% CI; 12.3, 29.5). ZAYNICH was generally well tolerated in the phase 3 study. The study enrolled 530 patients from the U.S., Europe, LATAM, China and India, and spanned across 64 sites.
